ArticleScience progress
Expression and clinical significance of TEM8 protein in triple-negative breast cancer.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and ObjectivesTumor Endothelial Marker 8 (TEM8) is integral to angiogenesis, tumor microenvironment remodeling, and cancer cell proliferation, and its expression is upregulated in a variety of malignancies. Despite its potential as both a prognostic biomarker and a therapeutic target in triple-negative breast cancer (TNBC), the exact role of TEM8 in TNBC remains poorly understood. This study seeks to examine the expression of TEM8 protein in TNBC and explore its associations with clinicopathological characteristics and patient survival outcomes.MethodsClinical and pathological data from 118 patients diagnosed with TNBC via surgical pathology between January 2015 and December 2017 were retrospectively analyzed at Harbin Medical University Cancer Hospital. A total of 35 adjacent non-cancerous tissue samples were randomly selected from the tumor tissue samples of the 118 TNBC patients. Immunohistochemistry (IHC) was employed to assess the expression levels of TEM8 and CD31 proteins. The correlations between TEM8 expression and various clinicopathological features, as well as survival status, were analyzed.ResultThe positive expression rate of TEM8 in TNBC tumor tissues was 89.8% (106/118), significantly higher than 60% (21/35) observed in adjacent non-tumorous tissues (χ
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.